Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of SX-682 and Atezolizumab in Patients With Advanced NSCLC Who Progressed on Prior Chemotherapy and Immune Checkpoint Inhibitor (ICI) Therapy

NCT07322341 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT07322341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07322341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of SX-682 and Atezolizumab in Patients With Advanced NSCLC Who Progressed on Prior Chemotherapy and Immune Checkpoint Inhibitor (ICI) Therapy
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
October 6, 2026
Completion date
November 1, 2031
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung non-small cell carcinoma, metastatic lung non-small cell carcinoma, recurrent lung non-small cell carcinoma, stage iii lung cancer ajcc v8, stage iv lung cancer ajcc v8